Exagamglogene Autotemcel (Casgevy)
CRISPR-based gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older.
What is Exagamglogene Autotemcel?
What it targets
Edits the BCL11A erythroid enhancer in hematopoietic stem cells to boost fetal hemoglobin production in red blood cells.
Who it may help
Patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta-thalassemia who meet eligibility criteria.
Why testing matters
Requires hemoglobin testing, CBC, organ function panels, iron assessment, infection screening, and specialist transplant evaluation.
Diseases treated with Exagamglogene Autotemcel
Casgevy is approved for two serious inherited blood disorders with high unmet need.
| Severe Sickle Cell Disease | For patients aged 12 and older with recurrent vaso-occlusive crises or other severe manifestations, when a gene therapy approach is considered appropriate by the treating team. |
| Transfusion-Dependent Beta-Thalassemia | For patients aged 12 and older who require regular red blood cell transfusions to maintain hemoglobin levels, when a gene therapy approach is clinically appropriate. |
| Other Inherited Blood Disorders | Use outside approved indications should only be considered in a clinical trial or at an expert center — not as standard practice. |
Who may be eligible for Casgevy?
Eligibility is determined at a specialist gene therapy or stem cell transplant center after a full medical evaluation.
- Confirmed diagnosis of severe sickle cell disease or transfusion-dependent beta-thalassemia.
- Age 12 years or older — as per FDA and EMA approved labelling.
- Adequate organ function including liver, kidney, heart, and lung assessments.
- Fit enough to undergo stem cell mobilization, myeloablative conditioning, and prolonged hospital monitoring.
- No active uncontrolled infection at the time of treatment planning.
- Suitable stem cell collection — adequate CD34+ cell yield required for manufacturing.
- Absence of severe uncontrolled organ damage that would make conditioning chemotherapy unsafe.
- For sickle cell disease: history of severe disease manifestations such as recurrent pain crises, acute chest syndrome, or stroke.
- Ability to attend long-term follow-up visits at the treating center.
- Fertility counselling completed — conditioning chemotherapy can cause infertility.
How does Exagamglogene Autotemcel work?
- Stem cell collection
- CRISPR/Cas9 gene editing
- Manufacturing and quality testing
- Conditioning chemotherapy
- Infusion of edited cells
- Engraftment and blood count recovery
Tests needed before Exagamglogene Autotemcel
A comprehensive pre-treatment evaluation is required at a specialist center before any gene therapy can begin.
| Hemoglobin electrophoresis / HPLC | Confirms diagnosis of sickle cell disease or beta-thalassemia and quantifies hemoglobin fractions. |
| Genetic testing | Beta-globin gene mutation analysis to confirm the specific variant and guide eligibility assessment where required. |
| Complete Blood Count (CBC) | Baseline blood counts including hemoglobin, white cells, and platelets to assess current disease status. |
| Liver function tests | Hepatic assessment required — liver disease may affect conditioning chemotherapy safety and eligibility. |
| Kidney function tests | Renal function assessment for safe conditioning chemotherapy planning and dosing. |
| Iron overload assessment | Serum ferritin and liver MRI (T2*) where indicated — iron overload is common in transfused patients and must be evaluated. |
| Cardiac evaluation | ECG and echocardiogram to assess heart function before myeloablative conditioning. |
| Lung function tests | Pulmonary function tests in selected patients, particularly those with prior acute chest syndrome or sickle lung disease. |
| Infection screening | Hepatitis B, hepatitis C, HIV, CMV, EBV, and other relevant infectious disease panels as per local transplant protocols. |
| Fertility counselling | Mandatory before conditioning chemotherapy — sperm banking, egg freezing, or embryo cryopreservation should be offered. |
| Stem cell collection planning | Assessment of vascular access, CD34+ cell mobilization response, and apheresis feasibility at the treating center. |
How is Exagamglogene Autotemcel given?
Casgevy is a one-time IV infusion, but the complete treatment journey spans several months across multiple stages.
| Route | Single intravenous infusion of the patient's own edited hematopoietic stem cells. |
| Manufacturing lead time | Stem cells are collected, edited, and manufactured over several weeks before the patient can proceed to conditioning. |
| Conditioning chemotherapy | Myeloablative conditioning with busulfan is given in hospital in the days before the cell infusion to prepare the bone marrow. |
| Infusion setting | Administered only at qualified gene therapy and stem cell transplant centers with transplant-level intensive care support. |
| Hospital stay | Patients require extended inpatient admission — typically several weeks — during conditioning and blood count recovery after infusion. |
| Duration of treatment effect | Designed as a one-time therapy with potentially lasting benefit; long-term follow-up continues for years after the single infusion. |
| Long-term follow-up | Regular visits for blood counts, fetal hemoglobin monitoring, organ function, infection surveillance, and safety assessment for years after treatment. |
Clinical evidence and potential benefits
Data from the CLIMB SCD-121 and CLIMB THAL-111 trials form the clinical basis for Casgevy's approval in sickle cell disease and beta-thalassemia respectively.
| Sickle cell disease — crisis freedom | In the CLIMB SCD-121 trial, the large majority of treated patients achieved freedom from severe vaso-occlusive crises after Casgevy, sustained over the follow-up period. |
| Beta-thalassemia — transfusion independence | In the CLIMB THAL-111 trial, most treated patients achieved transfusion independence, no longer requiring regular red blood cell transfusions after engraftment. |
| Elevated fetal hemoglobin | Edited cells produce substantially higher fetal hemoglobin levels than pre-treatment levels, which is the mechanism behind the clinical improvements seen in both conditions. |
| Improved anemia control | Patients who respond to treatment show improved hemoglobin levels and reduced anemia burden, supporting better quality of life and reduced organ complications over time. |
| No donor required | Because the therapy uses the patient's own cells, there is no need to find a matched unrelated or sibling donor, making it accessible to patients who lack a suitable transplant donor. |
| One-time therapy | Casgevy is designed as a single treatment with the potential for long-lasting benefit, avoiding the burden of chronic disease management therapies taken indefinitely. |
Individual responses vary. Clinical data comes from the CLIMB SCD-121 and CLIMB THAL-111 trials. Long-term follow-up is ongoing.
Side effects of Exagamglogene Autotemcel
Side effects arise from stem cell collection, myeloablative conditioning chemotherapy, the infusion, and the recovery period — not from the edited cells themselves. Many are related to the transplant process rather than the gene editing.
| Low blood counts (cytopenias) | Expected after conditioning — very low neutrophils, platelets, and red blood cells for several weeks while the new cells engraft. Managed with transfusions and growth factor support. |
| Serious infections | Severe immunosuppression during engraftment phase raises infection risk. Antibiotics, antifungals, and antiviral prophylaxis are given; fever requires immediate assessment. |
| Fever and febrile neutropenia | Common during low blood count period. Must be treated urgently at the treating center and never managed at home during this phase. |
| Mouth sores (mucositis) | Painful oral ulcers caused by conditioning chemotherapy. Managed with oral rinses, pain control, and nutritional support. |
| Nausea, vomiting, and diarrhea | Caused by conditioning chemotherapy. Antiemetics and supportive care are provided throughout conditioning. |
| Hair loss (alopecia) | Temporary hair loss from conditioning chemotherapy. Hair typically regrows after the conditioning phase is over. |
| Bleeding risk | Elevated while platelet counts are very low. Platelet transfusions are given as needed during the transplant period. |
| Fatigue and weakness | Profound fatigue is common throughout the treatment journey, particularly during conditioning and early recovery. May persist for several months. |
| Liver complications | Busulfan and conditioning can affect liver function. Regular liver function monitoring is performed throughout treatment. |
| Infusion reactions | Potential reactions at the time of cell infusion. Nursing and medical staff are present throughout the infusion for immediate management. |
| Delayed engraftment | Occasionally the edited cells take longer than expected to engraft, prolonging the period of low blood counts and hospitalization. |
| Fertility impairment | Myeloablative conditioning can cause temporary or permanent infertility. Fertility preservation before treatment is strongly recommended. |
Contact your medical team immediately if you experience:
- Fever of 38°C or higher — any fever during the low blood count phase is a medical emergency.
- Unusual bleeding, blood in urine, black stools, or unexplained bruising.
- Severe difficulty breathing or new chest pain at any point during treatment or recovery.
- New neurological symptoms including confusion, severe headache, weakness, or seizure.
- Jaundice, dark urine, or sudden onset abdominal pain — may indicate liver complications.
- Persistent severe vomiting preventing drinking or eating — requires urgent IV hydration.
Safety precautions and important considerations
Tell your hematology, transplant, and gene therapy team about all medical conditions, medicines, supplements, and personal circumstances before starting the treatment process.
- Liver disease — hepatic dysfunction may affect busulfan conditioning safety and eligibility.
- Kidney disease — renal impairment affects conditioning chemotherapy dosing and monitoring.
- Active infection — uncontrolled infections must be treated before proceeding to gene therapy.
- Pregnancy — Casgevy must not be given during pregnancy. Effective contraception is required.
- Breastfeeding — should be stopped before starting the treatment process; discuss with your care team.
- Fertility — conditioning chemotherapy can cause permanent infertility. Preserve fertility before starting.
- Prior allogeneic transplant — history of previous transplant may affect eligibility. Expert assessment required.
- Live vaccines — avoid live vaccines before, during, and for a period after treatment. Ask your team for the vaccination schedule.
- Iron overload — patients with significant iron overload may need iron chelation before or alongside treatment.
- Stroke or neurological history — sickle cell patients with prior stroke need specialist neurological assessment.
Casgevy and other treatments
Casgevy is a standalone gene therapy rather than a combination drug. However, supportive treatments are used throughout the treatment journey, and some prior disease therapies must be carefully managed around the treatment process.
| Supportive care throughout | Transfusions, antibiotics, antifungals, antivirals, pain management, and antiemetics are given before, during, and after Casgevy as standard transplant care. |
| Busulfan conditioning | Busulfan-based myeloablative conditioning is given immediately before the cell infusion. Anti-seizure medication is given alongside busulfan to prevent seizures. |
| Hydroxyurea — management before treatment | Patients taking hydroxyurea for sickle cell disease should discuss with their treating team when to continue, pause, or stop it in relation to stem cell mobilization and treatment. |
| Iron chelation therapy | Transfusion-dependent patients with significant iron overload may require chelation therapy before or after Casgevy. Ferritin and liver iron should be optimized where possible. |
| Allogeneic transplant vs. Casgevy | For patients with a matched sibling donor, allogeneic stem cell transplant remains an established option. Casgevy is relevant for patients who lack a suitable donor or where donor transplant carries high risk. |
If Exagamglogene Autotemcel does not achieve the expected benefit
Unlike chemotherapy resistance, the main concerns with Casgevy relate to insufficient engraftment, inadequate fetal hemoglobin induction, or complications that affect treatment response.
| Inadequate engraftment | If the edited cells do not fully engraft in the bone marrow, fetal hemoglobin levels may not rise enough to achieve clinical benefit. This can be assessed by blood counts and hemoglobin analysis. |
| Insufficient HbF induction | Some patients may produce more fetal hemoglobin than before treatment but not enough to achieve full transfusion independence or crisis freedom. Regular hemoglobin electrophoresis monitors response. |
| Ongoing disease burden | If the expected clinical benefit is not achieved, patients may continue to need transfusions, pain management, or hydroxyurea. The transplant team will assess and discuss remaining options. |
| Allogeneic transplant as an alternative | For patients in whom Casgevy does not provide sufficient benefit, allogeneic stem cell transplant may still be considered if a suitable donor is available and organ function permits. |
| Other emerging gene therapies | Betibeglogene autotemcel (Zynteglo) is another approved gene therapy for beta-thalassemia using a different approach. Clinical trials of next-generation gene editing strategies are ongoing. |
Cost of Exagamglogene Autotemcel (Casgevy)
Casgevy carries one of the highest list prices of any approved therapy, but total treatment cost includes hospital admission, conditioning, supportive care, and long-term follow-up — all of which add substantially to the direct drug cost.
| USA | List price is approximately USD 2.2 million for the therapy itself. Total treatment costs including conditioning, hospitalization, and follow-up are substantially higher. Insurance pre-authorization and patient assistance programs should be explored. |
| UK / Europe | NHS England reached an agreement with Vertex for Casgevy in sickle cell disease. Coverage details and access pathways vary by country. Patients in the EU should contact national health authorities or specialist centers for reimbursement information. |
| India | Casgevy is not yet locally approved or commercially available in India as of 2026. Indian patients seeking this therapy would need to travel to a qualified center in the USA or Europe. CancerFax can assist with cost planning and access coordination. |
| Gulf / Middle East | Access is limited and center-dependent. Some patients from Gulf countries travel to Europe or the USA for this therapy. Out-of-pocket costs are very high. Insurance coverage should be confirmed before initiating evaluation. |
| Other countries | Global availability is limited to centers with regulatory approval and gene therapy infrastructure. CancerFax can help identify whether treatment at an approved international center is feasible for patients in other regions. |
Global availability of Casgevy
Casgevy is available only at selected qualified gene therapy and stem cell transplant centers. Even in approved regions, not every hospital can administer this therapy.
USA
FDA approved in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older. Available at qualified treatment centers. Insurance coverage and patient assistance programs vary.
UK
MHRA approved and NHS England has a managed access agreement for sickle cell disease. Available at designated specialist centers. Patients should be referred through their hematologist.
European Union
EMA approved. National health authority reimbursement decisions vary by member state. Patients should contact their hematologist or national rare disease center for local access pathways.
India
Not yet locally approved or commercially available as of 2026. Indian patients would need evaluation and treatment at an approved center abroad. CancerFax can assist with international referral and coordination.
China
Casgevy is not yet approved in China as of 2026. China has an active domestic gene therapy research program. Clinical trial access may be available at selected centers — verify current trial status.
Middle East / Gulf
Limited access; some centers in the Gulf are developing gene therapy programs. Patients typically travel to Europe or the USA for Casgevy. Insurance pre-approval is essential.
Exagamglogene Autotemcel in clinical research
Long-term safety and efficacy data collection is ongoing, and research is expanding into younger age groups, new conditioning approaches, and broader access models.
| CLIMB SCD-121 long-term follow-up | Ongoing long-term study tracking vaso-occlusive crisis freedom, fetal hemoglobin levels, organ function, and safety in patients treated in the pivotal sickle cell disease trial. |
| CLIMB THAL-111 long-term follow-up | Ongoing extension study monitoring transfusion independence durability, hemoglobin levels, iron overload resolution, and long-term safety in treated beta-thalassemia patients. |
| Younger age groups | Research exploring Casgevy eligibility in patients younger than 12 years, where the disease burden is often severe and early intervention may be most beneficial. |
| Reduced-intensity conditioning | Studies evaluating whether less intensive conditioning regimens can achieve adequate engraftment with lower toxicity, particularly for patients with organ compromise. |
| Access and healthcare equity trials | Research into cost reduction, manufacturing scale-up, and access models for low- and middle-income countries where sickle cell disease and thalassemia burden is highest. |
Your treatment journey with Exagamglogene Autotemcel
Diagnosis and disease severity review
Specialist gene therapy consultation
Pre-treatment workup
Stem cell mobilization and collection
Manufacturing — cell editing
Conditioning chemotherapy
Casgevy infusion
Engraftment monitoring and hospital discharge
Response assessment
Long-term safety follow-up
Questions to ask your specialist about Casgevy
- Am I eligible for Casgevy based on my diagnosis and organ function?
- How does Casgevy compare to an allogeneic bone marrow transplant for my situation?
- Could this treatment affect my fertility, and what should I do before starting?
- How long will I need to be in hospital, and what support will I need at home?
- What is the total expected cost including conditioning, hospital stay, and follow-up?
- What infections or complications should I watch for after treatment?
- How will we know if the treatment has worked?
- What happens if Casgevy does not provide enough benefit?
How CancerFax supports Casgevy patients
CancerFax helps patients and families navigate gene therapy access, coordinate international specialist opinions, and plan for complex treatment journeys.
| Medical report review | Upload your hemoglobin reports, blood counts, genetic results, and organ function panels. Our team reviews them and explains their implications for Casgevy eligibility and timing. |
| Specialist connection | We connect patients with hematologists and gene therapy specialists in India, the USA, Europe, and internationally who have experience with Casgevy and hemoglobin disorders. |
| Second opinion coordination | If you are unsure whether Casgevy, allogeneic transplant, or another gene therapy is most appropriate, CancerFax arranges a second opinion with a specialist in your disease and geography. |
| International access planning | For patients outside the USA and Europe, we help map out which qualified treatment centers are accessible, estimate realistic total costs, and navigate travel and logistical planning. |
| Cost and insurance navigation | CancerFax can help identify patient assistance programs, insurance pre-authorization pathways, and international funding routes for high-cost therapies like Casgevy. |
| Clinical trial guidance | We help patients understand whether an approved therapy pathway or a clinical trial for emerging gene therapy approaches is more appropriate for their specific diagnosis and situation. |
Frequently asked questions about Casgevy
Common questions from patients and caregivers about CRISPR gene therapy for blood disorders
Casgevy (exagamglogene autotemcel) uses CRISPR/Cas9 technology to edit the patient's own stem cells outside the body before returning them. Unlike a bone marrow transplant, it does not require a matched donor because the cells come from the patient themselves. This removes the risks of rejection and graft-versus-host disease that are associated with allogeneic transplants.
Casgevy is a one-time gene therapy that has produced long-lasting benefit in clinical trials, with many patients achieving freedom from severe vaso-occlusive crises. However, long-term follow-up data beyond several years is still being collected, so doctors describe it as a potentially disease-modifying therapy rather than a guaranteed cure. Your hematologist can explain what the results mean for your individual situation.
Casgevy is approved for patients aged 12 years and older with severe sickle cell disease or transfusion-dependent beta-thalassemia. Eligibility depends on diagnosis confirmation, disease severity, age, organ function, infection status, and the ability to undergo conditioning chemotherapy and prolonged hospital monitoring. Not every patient with these conditions qualifies — a full assessment at a specialist gene therapy center is required.
Before receiving the edited cells, patients receive myeloablative conditioning chemotherapy — typically with busulfan — to clear the bone marrow and make space for the new cells. This is an intensive process that causes temporary loss of all blood cell production, significantly raising infection and bleeding risks for several weeks. All patients require inpatient monitoring in a specialist center during this phase, and close medical support is essential throughout.
Yes — conditioning chemotherapy can affect fertility in both males and females. Fertility preservation, such as sperm banking or egg/embryo freezing, should be discussed with your care team before starting treatment. This is a standard step in the pre-treatment evaluation and should not be skipped, especially for younger patients who may wish to have children in the future.
The complete treatment journey typically spans several months. Stem cell collection, laboratory editing, and manufacturing alone can take weeks. This is followed by conditioning chemotherapy, the infusion itself, and then several weeks of inpatient monitoring for blood count recovery. Long-term follow-up visits continue for years afterward to monitor safety, blood counts, and treatment response.
As of 2026, Casgevy is approved in the USA and Europe and is available at selected qualified treatment centers in those regions. Availability in India and other parts of Asia is limited and subject to local regulatory approval. CancerFax can help patients explore whether treatment at an approved international center is a feasible option and assist with coordinating second opinions, cost planning, and access pathways.
If the expected benefit is not achieved or complications occur, the specialist team will review blood counts, fetal hemoglobin levels, transfusion requirements, and marrow function. Some patients may still need supportive care including transfusions, iron chelation, and pain management. A second opinion at another gene therapy or stem cell transplant center can help families understand remaining options, including allogeneic transplant or other emerging therapies.